Acadia Pharmaceuticals (ACAD) PT Lowered to $31 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $31.00 (from $35.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
